RNS Number: 7785 J Silence Therapeutics PLC 21 August 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 100,000 new ordinary shares of 5 p each following the exercise of share options under the Employee...
RNS Number: 5319 J Silence Therapeutics PLC 19 August 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 82,375 new ordinary shares of 5 p each following the exercise of share options under the Employee...
RNS Number: 1012 J Silence Therapeutics PLC 15 August 2019 Silence Therapeutics Notice of Half Year Results and R&D Day. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, will announce results for the half year ending 30 June 2019, at 7:00am BST on Thursday 12...
RNS Number: 7917 I Silence Therapeutics PLC 13 August 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that yesterday it issued and allotted 200,000 new ordinary shares of 5 p each following the exercise of share options under the...
RNS Number: 4657 I Silence Therapeutics PLC 08 August 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 40,000 new ordinary shares of 5 p each following the exercise of share options under the Employee...
RNS Number: 2860 I Silence Therapeutics PLC 07 August 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 20,000 new ordinary shares of 5 p each following the exercise of share options under the Employee...
RNS Number: 1162 I Silence Therapeutics PLC 06 August 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 6,000 new ordinary shares of 5 p each following the exercise of share options under the Employee...
Silence Therapeutics Plc (SLN.L) Announced that Jørgen Wittendorff has been appointed to the new role of Head of Manufacturing at Silence Therapeutics. Joining the company's senior management team, he will be responsible for the process development and manufacturing of siRNA therapeutic products for clinical trials and, ultimately, commercial use.
LONDON, Silence Therapeutics, PLC, a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, is pleased to announce that Jørgen Wittendorff has been appointed to the new role of Head of Manufacturing at Silence Therapeutics. Most recently, he was Senior Director, CMC Manufacturing and Product Supply...
RNS Number: 6322 H Silence Therapeutics PLC 01 August 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 3411 H Silence Therapeutics PLC 31 July 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 2669 H Silence Therapeutics PLC 30 July 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 100,000 new ordinary shares of 5 p each following the exercise of share options under the Employee...
Silence Therapeutics Plc (SLN.L) Announced that further to the announcements on 18 July 2019 detailing the Company's collaboration with and equity investment by Mallinckrodt plc (NYSE: MNK), Steven Romano, MD, has today joined the Board of Silence as a Non-Executive Director.
RNS Number: 9484 G Silence Therapeutics PLC 29 July 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, is pleased to announce that further to the announcements on 18 July 2019 detailing the Company's collaboration with and equity investment by...
RNS Number: 9062 G Silence Therapeutics PLC 26 July 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 7475 G Silence Therapeutics PLC 25 July 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 5481 G Silence Therapeutics PLC 24 July 2019 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 4336 G Silence Therapeutics PLC 23 July 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 60,000 new ordinary shares of 5 p each following the exercise of share options under the Employee...
RNS Number: 1828 G Silence Therapeutics PLC 19 July 2019. The auction call period has been extended in this security by 5 minutes. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.
RNS Number: 1718 G Silence Therapeutics PLC 19 July 2019. LONDON, Silence Therapeutics, PLC a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 200,000 new ordinary shares of 5 p each following the exercise of share options under the Employee...
Bid
-
-
-
Ask
  • High
    -
  • OPEN
    -
  • VOL
    -
  • MKT CAP
    -m
  • LOW
    -
  • CLOSE
    -
  • AVG VOL
    -
  • SHARES IN ISSUE
    71.07M

Income Statement

Sales/Revenue
Gross Income
Operating Income
Net Interest Income
Pre-Tax Income
Consolidated Net Income
Non-Interest Income
Interest Income after Loan Loss Provision
Non-Operating Income
Operating Income (EBIT)
Net Income
Non-Interest Expense
Operating Expenses
Total Expense
Operating profit per share
EPS (Basic)
EPS (Diluted - Before Unusual Expense)
EPS (Fully Diluted)

Balance Sheet - Assets

Net Property, Plant & Equipment
Intangible Assets
Cash & Short Term Investments
Investments
Other Financial Assets
Inventories
Total Short Term Accounts Receivable
Total Accounts Receivable
Total Cash & Due from Banks
Premium Balance Receivables
Total Current Assets
Tangible Other Assets
Other Intangible Assets
Other Assets
Other Funds
Total Assets

Balance Sheet - Liabilities

Liabilities & Stockholders' Equity
Other Current Liabilities
Total Current Liabilities
Provision for Risks & Charges
Losses, Claims & Reserves
Other Liabilities
Total Liabilities

Balance Sheet - Other

Dividends Per Share (Gross)
Dividends Per Share
Dividends Per Share (1-yr Annual Growth)
Dividend payout per share
Common Shares
Common Shares Outstanding
Common Shares (EPS Basic)
Common Shares (EPS Diluted)
Closely Held Shares
Total Shareholders' Equity
Non-Equity Reserves
Retained Earnings
Total Equity
Pre-Tax Margin
Net Interest Margin
Gross Profit Margin
Net Margin
Operating Margin
P/E Ratio
Debt / EBITDA
Total Debt / Assets
Assets Per Employee
Current Ratio
Common Stock Par / Carry Value
Enterprise Value
Market Value
Market Capitalisation
Dividend Yield
Dividend Yield - Security
Cash Dividend Coverage Ratio

Miscellaneous

Total Debt
Restricted Cash
Exchange Rate Effect
Incomes Taxes
Net Change in Cash
Income Tax Payable
Cash Only
Cash Dividends Paid
Convertible Debt
Long Term Debt
Short Term Debt
Asset Turnover
EBITDA
Operating Income After Interest Expense
Net Debt
Operating Income Before Interest Expense
Purchase / Sale of Investments
Other Appropriated Reserves
Creditors
Watchlist